Expansion of Interleukin‐22– and Granulocyte–Macrophage Colony‐Stimulating Factor–Expressing, but Not Interleukin‐17A–Expressing, Group 3 Innate Lymphoid Cells in the Inflamed Joints of Patients With Spondyloarthritis

Autor: Sijia Chen, Leonike J. J. van Mens, S. Menegatti, Hergen Spits, Dominique Baeten, Lars Rogge, Talia E. Latuhihin, Hulda S. Hreggvidsdottir, Iris C Blijdorp, Troy Noordenbos, Nataliya Yeremenko, Marleen G H van de Sande, Jochem H. Bernink

Publikováno v: Arthritis & Rheumatology (Hoboken, N.j.)
Arthritis & rheumatology (Hoboken, N.J.), 71(3), 392-402. John Wiley and Sons Ltd
Arthritis & rheumatology
Arthritis & rheumatology, 2019, 71 (3), pp.392-402. ⟨10.1002/art.40736⟩
Arthritis & rheumatology, Wiley, 2019, 71 (3), pp.392-402. ⟨10.1002/art.40736⟩

International audience; Objective: Clinical trials of the anti-interleukin-17A (anti-IL-17A) antibody secukinumab have demonstrated a crucial role of the cytokine IL-17A in the pathogenesis of spondyloarthritis (SpA); however, its cellular source in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c7061c080fd7bb1563260905d5b4100
https://doi.org/10.1002/art.40736